ReviewF1000prime reports2015
Drug-induced liver injury: the dawn of biomarkers?
Review in F1000prime reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Angiotensin-Converting Enzyme Inhibitor-Drug Induced Liver Injury: Clinical Features and Diagnostic Features - A Systematic Review of Current Reported Cases.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Pooled it
- Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis.International journal of molecular sciences · 2022Article
- Acute and Subacute Toxicity Study of Essential Oil of Cymbopogon Martini in Mice.Journal of toxicology · 2022Article
- Drug-induced Fatty Liver Disease: Pathogenesis and Treatment.Journal of clinical and translational hepatology · 2021Review
- Π electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer.Biomaterials · 2021Article
- Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.Frontiers in pharmacology · 2019Review
- Pyrrole-protein adducts - A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity.Journal of food and drug analysis · 2018Review
- Alteration of Bile Acid and Cholesterol Biosynthesis and Transport by Perfluorononanoic Acid (PFNA) in Mice.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Defining baseline epigenetic landscapes in the rat liver.Epigenomics · 2017Article
- Review
- Drug-induced liver injury: Do we know everything?World journal of hepatology · 2017Review
- Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics.International journal of molecular sciences · 2017Article
- Novel circulating- and imaging-based biomarkers to enhance the mechanistic understanding of human drug-induced liver injury.Journal of clinical and translational research · 2017Review
- Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.Frontiers in pharmacology · 2017Article
- Current Biochemical Monitoring and Risk Management of Immunosuppressive Therapy after Transplantation.Journal of medical biochemistry · 2017Article
- Clinical decision support for drug related events: Moving towards better prevention.World journal of critical care medicine · 2016Review
- Review
- From hepatoprotection models to new therapeutic modalities for treating liver diseases: a personal perspective.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a potentially fatal adverse event with significant medical and economic impact. Many drugs, especially anti-infective, neurologic or pain-modifying substances, act as hepatotoxins. With cardiovascular toxicity, liver toxicity is one of the two leading causes for drug withdrawal from the market. The liver can be affected directly, in a predictable and dose-dependent manner, or idiosyncratically, independent of the dose and therefore unpredictable. Currently DILI is a diagnosis of exclusion that physicians have to bear in mind in patients with an unexplained increase of liver enzymes. The type of injury is categorized into hepatocellular, cholestatic, or mixed by the respective enzyme pattern of injury. Symptoms of affected patients can mimic any other liver disease. Therefore, new diagnostic and prognostic biomarkers for early liver injury are currently being evaluated in multi-centre clinical trials that are conducted by international consortia and other initiatives. Pharmacogenetic testing, next-generation sequencing, proteomics, metabolomics and mechanistic markers can help to preselect susceptible patient populations and tailor drug therapy to individual patients. Proposed DILI indicators that are under investigation include microRNAs, cytokeratin-18 (CK18), high mobility group box protein 1 (HMGB-1), and several other biomarkers. These developments can change clinical practice, and improve patients' safety and management. However, they have not been translated into clinical practice or approved for routine use yet. Management of DILI usually consists of initial withdrawal of the suspected drug and-if applicable-administration of specific antidotes, such as N-acetylcysteine. However, the overall management of DILI could change in the near future with the advent of novel diagnostic and prognostic DILI markers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.